Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.

Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB, Adult AIDS Clinical Trials Group
Clin Infect Dis. 2006 43 (6): 783-6

PMID: 16912957 · DOI:10.1086/507097

Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016).

MeSH Terms (24)

Adult Anti-HIV Agents Aryl Hydrocarbon Hydroxylases Case-Control Studies Chemical and Drug Induced Liver Injury Cytochrome P-450 CYP2B6 Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme System Female Gene Frequency Genes, MDR Genotype HIV-1 HIV Infections Humans Liver Liver Diseases Male Nevirapine Oxidoreductases, N-Demethylating Polymorphism, Genetic Randomized Controlled Trials as Topic Reverse Transcriptase Inhibitors South Africa

Connections (1)

This publication is referenced by other Labnodes entities: